{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:34:47Z","timestamp":1771014887326,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T00:00:00Z","timestamp":1490313600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Roche Farmac\u00eautica Qu\u00edmica, Lda."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s40258-017-0321-2","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T09:12:22Z","timestamp":1490346742000},"page":"501-512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost\u2010Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7162-1400","authenticated-orcid":false,"given":"Ana Teresa","family":"Paquete","sequence":"first","affiliation":[]},{"given":"Lu\u00eds Silva","family":"Miguel","sequence":"additional","affiliation":[]},{"given":"Ursula","family":"Becker","sequence":"additional","affiliation":[]},{"given":"Catarina","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Carlos Gouveia","family":"Pinto","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,3,24]]},"reference":[{"issue":"4","key":"321_CR1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1600-0609.2008.01114.x","volume":"81","author":"L Watson","year":"2008","unstructured":"Watson L, Wyld P, Catovsky D. Disease burden of chronic lymphocytic leukaemia within the European Union. Eur J Haematol. 2008;81(4):253\u20138.","journal-title":"Eur J Haematol"},{"issue":"19","key":"321_CR2","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724\u201334.","journal-title":"Blood"},{"key":"321_CR3","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","volume":"29","author":"V Goede","year":"2015","unstructured":"Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline of chronic lymphocytic leukemia: updated results of the CLL11 Study. Leukemia. 2015;29:1602\u20134.","journal-title":"Leukemia"},{"key":"321_CR4","unstructured":"INFARMED 2016. Reimbursement assessment report of obinutuzumab in CLL. Available from http:\/\/www.infarmed.pt\/documents\/15786\/1424140\/RelatorioPublico_Gazyvaro_obinutuzumab.pdf\/bf56ae0f-aa28-4bb1-b3df-e5ac70562a06 . Latest Access in 22-12-2016."},{"issue":"Suppl 6","key":"321_CR5","doi-asserted-by":"crossref","first-page":"vi50","DOI":"10.1093\/annonc\/mdr377","volume":"22","author":"B Eichhorst","year":"2011","unstructured":"Eichhorst B, Dreyling M, Robak T, Monserrat E, Hallek M. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi50\u20134.","journal-title":"Ann Oncol"},{"key":"321_CR6","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Non-Hodgkin\u2019s Lymphomas. Version 2.2014. March 37, 2014. Latest Access in 11-07-2014."},{"key":"321_CR7","unstructured":"Silva EA, Pinto CG, Sampaio C, Pereira JA, Drummond M e Trindade R, Orienta\u00e7\u00f5es Metodol\u00f3gicas para Estudos de Avalia\u00e7\u00e3o Econ\u00f3mica de Medicamentos, INFARMED; 1998."},{"key":"321_CR8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40273-013-0032-y","volume":"31","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Pharmacoeconomics. 2013;31:361\u20137.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"321_CR9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jval.2015.12.018","volume":"19","author":"U Becker","year":"2016","unstructured":"Becker U, Briggs AH, Moreno S, et al. Cost-effectiveness model for chemoimmunotherapy options in patients with previously untreated chronic lymphocytic leukemia unsuitable for full-dose fludarabine-based therapy. Value Health. 2016;19(4):364\u201382.","journal-title":"Value Health"},{"key":"321_CR10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, et al. Obinutuzumab plus Chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101\u201310.","journal-title":"N Engl J Med"},{"key":"321_CR11","unstructured":"INE (Statistics Portugal) 2014, Portuguese general population mortality tables\u00a02011\u20132013."},{"key":"321_CR12","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","volume":"114","author":"BF Eichhorst","year":"2009","unstructured":"Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009;114:3382\u201391.","journal-title":"Blood"},{"key":"321_CR13","unstructured":"NICE. Guide to the methods of technology appraisal 2013. Available from http:\/\/publications.nice.org.uk\/pmg9 ."},{"key":"321_CR14","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3109\/10428194.2014.961012","volume":"56","author":"CE Kosmas","year":"2015","unstructured":"Kosmas CE, Shingler SL, Samanta K, et al. Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression free survival. Leuk Lymphoma. 2015;56:1320\u20136.","journal-title":"Leuk Lymphoma"},{"key":"321_CR15","volume-title":"Interview","author":"B Eichhorst","year":"2014","unstructured":"Eichhorst B. Interview. Cologne: Department I of Internal Medicine, University Hospital of Cologne; 2014."},{"key":"321_CR16","unstructured":"Minist\u00e9rio da Sa\u00fade, Di\u00e1rio da Rep\u00fablica, N\u00ba 153 (Portaria n\u00ba 234\/2015) de 7 de agosto de 2015."},{"key":"321_CR17","unstructured":"ACSS, I.P. \u2013 Administra\u00e7\u00e3o Central do Sistema de Sa\u00fade, Contabilidade Anal\u00edtica 2006 \u2013 Hospitais do SNS, 2007. http:\/\/www2.acss.min-saude.pt\/Portals\/0\/DownloadsPublicacoes\/SNS\/Info_gestao\/Contab_Analitica_2006_Hospitais_SNS.pdf ."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-017-0321-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-017-0321-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-017-0321-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T09:33:44Z","timestamp":1601804024000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-017-0321-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,24]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1007\/s40258-017-0321-2","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,24]]}}}